Here are the DEF 14A proxy statements from Caris Life Sciences, Inc. (CAI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAI filings page.
Caris Life Sciences, Inc. is asking shareholders to vote at its June 4, 2026 virtual annual meeting on two items: electing ten directors to one‑year terms and ratifying Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026.
The board is led by founder, Chairman and CEO David Dean Halbert, with Peter M. Castleman serving as lead independent director. A majority of directors are classified as independent under Nasdaq rules, and the board maintains separate Audit and Compensation Committees composed entirely of independent members.
The proxy details 2025 executive pay, including total compensation of $20,350,571 for Mr. Halbert and $11,583,227 for President David Spetzler, driven largely by RSU and option awards granted around the June 2025 IPO. Senior executives have severance protections and participate in a change‑in‑control equity vesting plan, and the company operates multiple shareholder‑approved equity plans.